Angina therapies
Executive Summary
FDA's Cardio-Renal Drugs Advisory Committee will address all organic nitrates for long-term treatment of angina at its next meeting, scheduled for Jan. 26-27 at Jack Masur Auditorium on the NIH campus. The meeting is likely to include a discussion of efficacy data for transdermal nitroglycerin patches. Three patch marketers, Schering (Key's Nitro-Dur), Ciba-Geigy (Transderm-Nitro) and Searle (Nitro-disc), jointly sponsored a study to look at the efficacy of nitroglycerin patches....
You may also be interested in...
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: